Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 153 No. 10 (2023)

Management of biliary obstruction in patients with newly diagnosed alveolar echinococcosis: a Swiss retrospective cohort study

  • Sandra Müller
  • Soleen Ghafoor
  • Cordula Meyer zu Schwabedissen
  • Felix Grimm
  • Fritz Ruprecht Murray
  • Lars Husmann
  • Nadine Stanek
  • Peter Deplazes
  • Christoph Schlag
  • Andreas E. Kremer
  • Christoph Gubler
  • Cäcilia S. Reiner
  • David Semela
  • Beat Müllhaupt
  • Ansgar Deibel
DOI
https://doi.org/10.57187/smw.2023.40116
Cite this as:
Swiss Med Wkly. 2023;153:40116
Published
06.10.2023

Summary

BACKGROUND AND STUDY AIMS: Alveolar echinococcosis, an orphan zoonosis affecting the liver, is of increasing concern worldwide. Most symptomatic cases present at an advanced and inoperable stage, sometimes with biliary obstruction prompting biliary tract interventions. These are, however, associated with a high risk of infectious complications. The aim of this retrospective study was to compare the effectiveness and safety of conservative and interventional treatment approaches in patients with newly diagnosed alveolar echinococcosis and biliary obstruction.

PATIENTS AND METHODS: Alveolar echinococcosis patients treated at two referral centres in Switzerland, presenting with hyperbilirubinaemia (total bilirubin >1.5 Upper Limit of Normal) at diagnosis were included, unless another underlying aetiology, i.e. common bile duct stones or decompensated cirrhosis, was identified. Patients were divided into two groups, according to whether they initially received a biliary tract intervention. The primary endpoint was normalisation of bilirubin levels within a 6-month period. Secondary endpoints included, among others, the occurrence of early and late biliary complications, the need for biliary tract interventions during follow-up and overall duration of hospital stays for treatment initiation and for biliary complications.

RESULTS: 28 patients were included in this study, of whom 17 received benzimidazole therapy alone and 11 additionally received a biliary tract intervention. Baseline characteristics did not differ between groups. All but one patient in each group achieved the primary endpoint (p=0.747). Biliary tract intervention was associated with faster laboratory improvement (t1/2 1.3 vs 3.0 weeks), but also with more frequent early biliary complications (7/11 vs 1/17, p=0.002) and longer initial hospital stay (18 days vs 7 days, p=0.007).

CONCLUSION: Biliary obstruction in patients with newly diagnosed alveolar echinococcosis can be treated effectively with benzimidazole therapy alone. Biliary tract intervention, on the other hand, is associated with a high complication rate and should probably be reserved for patients with insufficient response to benzimidazole therapy.

References

  1. Eckert J, Deplazes P. Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern. Clinical microbiology reviews. 2004;17(1):107-35. Epub 2004/01/17. doi: 10.1128/cmr.17.1.107-135.2004. PubMed PMID: 14726458; PubMed Central PMCID: PMCPMC321468. 10.1128/CMR.17.1.107-135.2004 DOI: https://doi.org/10.1128/CMR.17.1.107-135.2004
  2. Romig T, Deplazes P, Jenkins D, Giraudoux P, Massolo A, Craig PS, et al. Ecology and Life Cycle Patterns of Echinococcus Species. Adv Parasitol. 2017;95:213-314. Epub 20170106. doi: 10.1016/bs.apar.2016.11.002. PubMed PMID: 28131364. DOI: https://doi.org/10.1016/bs.apar.2016.11.002
  3. Kern P, Menezes da Silva A, Akhan O, Müllhaupt B, Vizcaychipi KA, Budke C, et al. The Echinococcoses: Diagnosis, Clinical Management and Burden of Disease. Adv Parasitol. 2017;96:259–369. 10.1016/bs.apar.2016.09.006 DOI: https://doi.org/10.1016/bs.apar.2016.09.006
  4. Kern P, Wen H, Sato N, Vuitton DA, Gruener B, Shao Y, et al. WHO classification of alveolar echinococcosis: principles and application. Parasitol Int. 2006;55 Suppl:S283–7. 10.1016/j.parint.2005.11.041 DOI: https://doi.org/10.1016/j.parint.2005.11.041
  5. Ammann RW, Hoffmann AF, Eckert J. [Swiss study of chemotherapy of alveolar echinococcosis—review of a 20-year clinical research project]. Schweiz Med Wochenschr. 1999 Feb;129(8):323–32.
  6. Brunetti E, Kern P, Vuitton DA; Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010 Apr;114(1):1–16. 10.1016/j.actatropica.2009.11.001 DOI: https://doi.org/10.1016/j.actatropica.2009.11.001
  7. Torgerson PR, Schweiger A, Deplazes P, Pohar M, Reichen J, Ammann RW, et al. Alveolar echinococcosis: from a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years. J Hepatol. 2008 Jul;49(1):72–7. 10.1016/j.jhep.2008.03.023 DOI: https://doi.org/10.1016/j.jhep.2008.03.023
  8. Ammann RW, Renner EC, Gottstein B, Grimm F, Eckert J, Renner EL; Swiss Echinococcosis Study Group. Immunosurveillance of alveolar echinococcosis by specific humoral and cellular immune tests: long-term analysis of the Swiss chemotherapy trial (1976-2001). J Hepatol. 2004 Oct;41(4):551–9. 10.1016/j.jhep.2004.06.015 DOI: https://doi.org/10.1016/j.jhep.2004.06.015
  9. Reuter S, Schirrmeister H, Kratzer W, Dreweck C, Reske SN, Kern P. Pericystic metabolic activity in alveolar echinococcosis: assessment and follow-up by positron emission tomography. Clin Infect Dis. 1999 Nov;29(5):1157–63. 10.1086/313438 DOI: https://doi.org/10.1086/313438
  10. Ammann RW, Stumpe KD, Grimm F, Deplazes P, Huber S, Bertogg K, et al. Outcome after Discontinuing Long-Term Benzimidazole Treatment in 11 Patients with Non-resectable Alveolar Echinococcosis with Negative FDG-PET/CT and Anti-EmII/3-10 Serology. PLoS neglected tropical diseases. 2015;9(9):e0003964. Epub 2015/09/22. doi: 10.1371/journal.pntd.0003964. PubMed PMID: 26389799; PubMed Central PMCID: PMCPMC4577091. DOI: https://doi.org/10.1371/journal.pntd.0003964
  11. Deibel A, Stocker D, Meyer Zu Schwabedissen C, Husmann L, Kronenberg PA, Grimm F, et al. Evaluation of a structured treatment discontinuation in patients with inoperable alveolar echinococcosis on long-term benzimidazole therapy: A retrospective cohort study. PLoS neglected tropical diseases. 2022;16(1):e0010146. Epub 20220128. doi: 10.1371/journal.pntd.0010146. PubMed PMID: 35089933; PubMed Central PMCID: PMCPMC8827419. DOI: https://doi.org/10.1371/journal.pntd.0010146
  12. Caoduro C, Porot C, Vuitton DA, Bresson-Hadni S, Grenouillet F, Richou C, et al. The role of delayed 18F-FDG PET imaging in the follow-up of patients with alveolar echinococcosis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2013;54(3):358-63. Epub 2013/01/11. doi: 10.2967/jnumed.112.109942. PubMed PMID: 23303963. DOI: https://doi.org/10.2967/jnumed.112.109942
  13. Schweiger A, Ammann RW, Candinas D, Clavien PA, Eckert J, Gottstein B, et al. Human alveolar echinococcosis after fox population increase, Switzerland. Emerging infectious diseases. 2007;13(6):878-82. Epub 2007/06/08. doi: 10.3201/eid1306.061074. PubMed PMID: 17553227; PubMed Central PMCID: PMCPMC2792858. DOI: https://doi.org/10.3201/eid1306.061074
  14. Chauchet A, Grenouillet F, Knapp J, Richou C, Delabrousse E, Dentan C, et al.; FrancEchino Network. Increased incidence and characteristics of alveolar echinococcosis in patients with immunosuppression-associated conditions. Clin Infect Dis. 2014 Oct;59(8):1095–104. 10.1093/cid/ciu520
  15. Deibel A, Meyer zu Schwabedissen C, Husmann L, Grimm F, Deplazes P, Reiner CS, et al. Characteristics and Clinical Course of Alveolar Echinococcosis in Patients with Immunosuppression-Associated Conditions: A Retrospective Cohort Study. Pathogens. 2022;11(4):441. PubMed PMID: doi:10.3390/pathogens11040441. DOI: https://doi.org/10.3390/pathogens11040441
  16. Paternoster G, Boo G, Wang C, Minbaeva G, Usubalieva J, Raimkulov KM, et al. Epidemic cystic and alveolar echinococcosis in Kyrgyzstan: an analysis of national surveillance data. Lancet Glob Health. 2020 Apr;8(4):e603–11. 10.1016/s2214-109x(20)30038-3 10.1016/S2214-109X(20)30038-3 DOI: https://doi.org/10.1016/S2214-109X(20)30038-3
  17. Gottstein B, Deplazes P. Alveolar echinococcosis: what triggers emergence in North America, Central Europe and Asia? Curr Opin Infect Dis. 2021 Oct;34(5):440–6. 10.1097/qco.0000000000000765 10.1097/QCO.0000000000000765 DOI: https://doi.org/10.1097/QCO.0000000000000765
  18. Bresson-Hadni S, Spahr L, Chappuis F. Hepatic Alveolar Echinococcosis. Seminars in liver disease. 2021;41(3):393-408. Epub 20210623. doi: 10.1055/s-0041-1730925. PubMed PMID: 34161992. DOI: https://doi.org/10.1055/s-0041-1730925
  19. Deplazes P, Hegglin D, Gloor S, Romig T. Wilderness in the city: the urbanization of Echinococcus multilocularis. Trends Parasitol. 2004 Feb;20(2):77–84. 10.1016/j.pt.2003.11.011 DOI: https://doi.org/10.1016/j.pt.2003.11.011
  20. Romig T, Thoma D, Weible AK. Echinococcus multilocularis—a zoonosis of anthropogenic environments? J Helminthol. 2006 Jun;80(2):207–12. 10.1079/joh2006347 10.1079/JOH2006347 DOI: https://doi.org/10.1079/JOH2006347
  21. Grüner B, Kern P, Mayer B, Gräter T, Hillenbrand A, Barth TE, et al. Comprehensive diagnosis and treatment of alveolar echinococcosis: A single-center, long-term observational study of 312 patients in Germany. GMS infectious diseases. 2017;5:Doc01. Epub 2017/01/06. doi: 10.3205/id000027. PubMed PMID: 30671323; PubMed Central PMCID: PMCPMC6301735.
  22. Piarroux M, Piarroux R, Giorgi R, Knapp J, Bardonnet K, Sudre B, et al. Clinical features and evolution of alveolar echinococcosis in France from 1982 to 2007: results of a survey in 387 patients. J Hepatol. 2011 Nov;55(5):1025–33. 10.1016/j.jhep.2011.02.018 DOI: https://doi.org/10.1016/j.jhep.2011.02.018
  23. Ozturk G, Polat KY, Yildirgan MI, Aydinli B, Atamanalp SS, Aydin U. Endoscopic retrograde cholangiopancreatography in hepatic alveolar echinococcosis. J Gastroenterol Hepatol. 2009 Aug;24(8):1365–9. 10.1111/j.1440-1746.2009.05877.x DOI: https://doi.org/10.1111/j.1440-1746.2009.05877.x
  24. Stojkovic M, Junghanss T, Veeser M, Weber TF, Sauer P. Endoscopic Treatment of Biliary Stenosis in Patients with Alveolar Echinococcosis--Report of 7 Consecutive Patients with Serial ERC Approach. PLoS neglected tropical diseases. 2016;10(2):e0004278. Epub 2016/02/26. doi: 10.1371/journal.pntd.0004278. PubMed PMID: 26910822; PubMed Central PMCID: PMCPMC4766234. DOI: https://doi.org/10.1371/journal.pntd.0004278
  25. Ambregna S, Koch S, Sulz MC, Grüner B, Öztürk S, Chevaux JB, et al. A European survey of perendoscopic treatment of biliary complications in patients with alveolar echinococcosis. Expert Rev Anti Infect Ther. 2017 Jan;15(1):79–88. 10.1080/14787210.2017.1252260 DOI: https://doi.org/10.1080/14787210.2017.1252260
  26. Schweiger A, Grimm F, Tanner I, Müllhaupt B, Bertogg K, Müller N, et al. Serological diagnosis of echinococcosis: the diagnostic potential of native antigens. Infection. 2012 Apr;40(2):139–52. 10.1007/s15010-011-0205-6 DOI: https://doi.org/10.1007/s15010-011-0205-6
  27. Reuter S, Grüner B, Buck AK, Blumstein N, Kern P, Reske SN. Long-term follow-up of metabolic activity in human alveolar echinococcosis using FDG-PET. Nucl Med (Stuttg). 2008;47(4):147–52. 10.3413/nukmed-0139 DOI: https://doi.org/10.3413/nukmed-0139
  28. Dumonceau JM, Tringali A, Papanikolaou IS, Blero D, Mangiavillano B, Schmidt A, et al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated October 2017. Endoscopy. 2018;50(9):910-30. Epub 20180807. doi: 10.1055/a-0659-9864. PubMed PMID: 30086596. DOI: https://doi.org/10.1055/a-0659-9864

Most read articles by the same author(s)

<< < 1 2 3